Enovis (ENOV) Income from Continuing Operations (2010 - 2026)
Enovis' (ENOV) quarterly Income from Continuing Operations came in at -$1.0 million in Q3 2026, up 97.16% year-over-year from -$525466.5 in Q3 2025, and up 87.68% quarter-over-quarter from -$8.4 million in Q2 2026.
Analysis
Enovis (ENOV) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Enovis (ENOV) has reported Income from Continuing Operations for 17 consecutive years, with -$1.0 million the latest figure, recorded in Q3 2026.
- On a quarterly basis, Income from Continuing Operations rose 97.16% year-over-year to -$1.0 million in Q3 2026; TTM through Jul 2026 was -$1.1 billion, a 32.56% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 42.82% from the prior year.
- Income from Continuing Operations was -$1.0 million for Q3 2026 at Enovis, up from -$8.4 million in the prior quarter.
- Over five years, Income from Continuing Operations peaked at $120.7 million in Q3 2022 and troughed at -$703.6 million in Q4 2024.
- A 5-year average of -$117.3 million and a median of -$35.0 million in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 386.51% in 2022 and plunged 23034.35% in 2024, its largest moves.
- Over 5 years, Income from Continuing Operations stood at -$54.8 million in 2022, then jumped by 105.59% to $3.1 million in 2023, then sank by 23034.35% to -$703.6 million in 2024, then climbed by 26.27% to -$518.8 million in 2025, then jumped by 99.8% to -$1.0 million in 2026.
- The last three Income from Continuing Operations figures came in at -$1.0 million (Q3 2026), -$8.4 million (Q2 2026), and -$518.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.92 Bn | 176.31 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 127.64 Bn | 122.42 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.92 Bn | 109.10 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 105.39 Bn | 101.91 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 64.88 Bn | 64.34 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.92 Bn | 45.66 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.24 Bn | 31.79 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.12 Bn | 30.18 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 20.83 Bn | 20.35 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Enovis | 1.08 Bn | 1.06 Bn | 359.25 Mn | -1.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | -1.04 Mn |
| Apr 3, 2026 | -8.41 Mn |
| Dec 31, 2025 | -518.80 Mn |
| Oct 3, 2025 | -570.87 Mn |
| Jul 4, 2025 | -36.46 Mn |
| Apr 4, 2025 | -55.58 Mn |
| Dec 31, 2024 | -703.63 Mn |
| Sep 27, 2024 | -33.51 Mn |
| Jun 28, 2024 | -18.44 Mn |
| Mar 29, 2024 | -71.84 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Sep 29, 2023 | -19.45 Mn |
| Jun 30, 2023 | -14.61 Mn |
| Mar 31, 2023 | -22.85 Mn |
| Dec 31, 2022 | -54.84 Mn |
| Sep 30, 2022 | -65.95 Mn |
| Jul 1, 2022 | 120.65 Mn |
| Apr 1, 2022 | -38.10 Mn |
| Dec 31, 2021 | -14.74 Mn |
| Oct 1, 2021 | -13.53 Mn |